Data Insights

MIL-62 by Beijing Mabworks Biotech for Marginal Zone B-cell Lymphoma: Likelihood of Approval

MIL-62 is under clinical development by Beijing Mabworks Biotech and currently in Phase III for Marginal Zone B-cell Lymphoma. According...

Data Insights

MIL-62 by Beijing Mabworks Biotech for Follicular Lymphoma: Likelihood of Approval

MIL-62 is under clinical development by Beijing Mabworks Biotech and currently in Phase III for Follicular Lymphoma. According to GlobalData,...

Data Insights

MIL-62 by Beijing Mabworks Biotech for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

MIL-62 is under clinical development by Beijing Mabworks Biotech and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According...

Data Insights

MIL-62 by Beijing Mabworks Biotech for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

MIL-62 is under clinical development by Beijing Mabworks Biotech and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - MIL-62 in Chronic Lymphocytic Leukemia (CLL)

Data Insights

MIL-62 by Beijing Mabworks Biotech for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval

MIL-62 is under clinical development by Beijing Mabworks Biotech and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - MIL-62 in Splenic Marginal Zone B-Cell Lymphoma

Data Insights

MIL-62 by Beijing Mabworks Biotech for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

MIL-62 is under clinical development by Beijing Mabworks Biotech and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma...

Likelihood of Approval and Phase Transition Success Rate Model - MIL-62 in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)